Madrigal Pharmaceuticals Inc. has expanded its pipeline for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) through an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals AB. The agreement brings six preclinical small interfering RNA (siRNA) programs into Madrigal’s portfolio, allowing the company to develop next-generation therapies that silence genes implicated in MASH. This move positions Madrigal as a leader in the MASH treatment landscape, building on its foundational therapy, Rezdiffra, and expanding its pipeline to more than 10 programs targeting various drivers of the disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9652512) on February 11, 2026, and is solely responsible for the information contained therein.